Pancreatic Cancer Research

Clinical trialPhase 2Terminated

Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine

A Phase II Pilot Study of Disulfiram and Copper Gluconate in Patients With Metastatic Pancreatic Cancer and Rising CA-19-9 Levels While Receiving Abraxane-Gemcitabine or FOLFIRINOX or Single-Agent Gemcitabine

Outcome
Stopped early. Results posted; no primary outcome with dataStudy was closed due to low subject enrollment at site. (Enrollment)
Phase
Phase 2
Status
Terminated
Study type
Interventional
Start
17 October 2019
Ended
29 July 2020
Enrollment
1 participants
Sites
1
Primary outcomes
CA19-9 Plasma Level
Sponsor type
Academic / other
Results posted
18 October 2023
Last update
18 October 2023

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Results posted; no primary outcome with dataAs posted on ClinicalTrials.gov ↗, registry record of 18 October 2023
Primary outcome, no data
CA19-9 Plasma LevelThe registry’s note: One patient was treated. This patient was on study for 6 weeks and ended trial participation due to progressive disease.
Participants
Nab-Paclitaxel/Gemcitabine + DSF/Cu: 1 started, 0 completedFOLFIRINOX +DSF/Cu: 0 started, 0 completedSingle-Agent Gemcitabine +DSF/Cu: 0 started, 0 completed
Serious adverse events
Nab-Paclitaxel/Gemcitabine + DSF/Cu: 1 of 1FOLFIRINOX +DSF/Cu: 0 of 0Single-Agent Gemcitabine +DSF/Cu: 0 of 0Participants with at least one serious adverse event, of those at risk, as posted

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is an open-label Phase 2 Pilot study to evaluate Disulfiram + Copper Gluconate in patients metastatic pancreatic cancer whose CA-19-9 levels rise while receiving nab-paclitaxel (Abraxane) plus gemcitabine (Gemzar) or FOLFIRINOX or single-agent gemcitabine (Gemzar). Patient must have received a minimum of 8 weeks of treatment and have rising CA-19-9 levels in the absence of radiographic evidence of progression.

Detailed description public domain (ClinicalTrials.gov)

This study has 3 arms with 5 patients enrolled in each of the three arms. The three treatment arms are based upon whether the patient has previously received Abraxane-Gemcitabine or FOLFIRINOX or single-agent Gemcitabine without radiographic evidence of disease progression for a minimum of 8 weeks , based on the investigator's opinion, but with a rising Carbohydrate antigen 19-9 (CA 19-9) levels. Rising CA 19-9 is defined as an increased over baseline of \> 20% in two consecutive time points within 8 days of each other. Study sites will provide all chemotherapy for patients participating in the study as a "standard of care". DSF/Cu (Disulfiram + Copper Gluconate) will be provided by the Sponsor and shipped from the Sponsor's central depot to the study sites. Sufficient amounts of DSF/Cu will be available at the study site prior to enrolling patients in the study.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

CA19-9 Plasma Level [From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months].

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Complete Tumor Response [From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months].

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Partial Response [From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months].

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Stable Disease [From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months].

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Overall Response Rate [From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months].

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Overall Survival [From date of enrollment until date of death assessed up to 100 months].

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Serum Albumin [From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months].

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Body Weight [From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months].

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Muscle Area at the L3 Level - Optional [From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months].

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Incidence of Toxicities [From date of enrollment until the date of follow-up, 30 days after last treatment].